CRMD - Company ID 0001410098
The table below shows CorMedix Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $127.43M | $104.28M | $39.74M | $39.08M | $11.46M | $806.12K |
| Cost of revenue | $12.01M | $7.57M | $1.86M | $1.54M | $634.65K | $509.84K |
| Gross profit | $105.12M | $93.08M | $37.87M | $37.48M | $10.77M | $296.28K |
| R&D | $7.21M | $5.10M | $2.44M | $3.19M | $727.12K | $650.99K |
CorMedix Inc. reported annual revenue of $311.71M for fiscal year 2025. That is up 617.0% from $43.47M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $210.13K (FY 2015) to $311.71M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $21.72M | $25.45M | $9.50M | $9.69M | $6.58M | $7.56M |
| Operating income | $63.66M | $51.35M | $19.54M | $20.13M | -$3.29M | -$15.30M |
| Income tax | $17.04M | -$55.99M | $521.51K | $0.00 | - | - |
| Net income | $38.60M | $108.56M | $19.83M | $20.64M | -$2.78M | -$14.15M |
| EPS (diluted) | $0.43 | $1.26 | $0.28 | $0.30 | -$0.05 | -$0.25 |